Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

4.10
+0.29007.61%
Post-market: 4.250.1500+3.66%19:58 EST
Volume:1.68M
Turnover:6.91M
Market Cap:366.33M
PE:-7.54
High:4.26
Open:3.86
Low:3.82
Close:3.81
52wk High:13.99
52wk Low:2.86
Shares:89.35M
Float Shares:83.05M
Volume Ratio:0.98
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5438
EPS(LYR):-0.5438
ROE:-43.11%
ROA:-26.51%
PB:3.86
PE(LYR):-7.54

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 06

Anavex Life Sciences Corp. kündigt Bekanntgabe neuer Finanzergebnisse an

Reuters
·
Feb 03

Anavex Life Sciences on Track for Highest Close Since November 2025 -- Data Talk

Dow Jones
·
Jan 21

Anavex Joins ACCESS-AD Consortium to Advance Precision Medicine in Alzheimer’s Disease

Reuters
·
Jan 13

BRIEF-Anavex Life Sciences Appoints Senior Vice President Global Head Of Neurology

Reuters
·
Jan 08

Anavex Life Sciences Appoints Wolfgang Liedtke as Senior Vice President, Global Head of Neurology

Reuters
·
Jan 08

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 06

Anavex Life Sciences Corp - Discussion on Potential Pathways for Nda for Alzheimer's Treatment

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Corp: Existing Data From Phase Iib/Iii Anavex2-73-Ad-004 Program Requested by Agency Will Be Submitted

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Corp - FDA Shows Interest in Anavex's Development Plans

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

GlobeNewswire
·
Jan 06

Anavex Life Sciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 22, 2025

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 19, 2025

Anavex Life Sciences Corp - Requests Ema to Re-Examine Blarcamesine for Alzheimer's

THOMSON REUTERS
·
Dec 18, 2025

Anavex Life Sciences Requests EMA Re-Examination of Alzheimer's Drug Blarcamesine

Reuters
·
Dec 18, 2025

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 15, 2025

EU Regulator Rejects Anavex Alzheimer's Drug Application

Reuters
·
Dec 13, 2025

Anavex Life Sciences Corp - Chmp Adopts Negative Opinion on Blarcamesine for Alzheimer's

THOMSON REUTERS
·
Dec 13, 2025

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

THOMSON REUTERS
·
Dec 13, 2025

Anavex Life Sciences Up Nearly 21%, on Pace for Largest Percent Increase Since December 2024 -- Data Talk

Dow Jones
·
Dec 04, 2025